Economic value of pre-travel health interventions for communicable diseases in international travellers
Cost-effectiveness analyses of pre-travel interventions can inform the value of such interventions, but such analyses depend on the availability of high-quality data regarding clinical outcomes and costs. We propose that international, collaborative networks should collect data and leverage novel technologies to expand the evidence base regarding the risks of exposure, clinical outcomes, risk perception, and costs associated with pre-travel interventions. This evidence base can inform recommendations for specific groups of travellers and the formulation of population-specific health policies.
Authors
- Allison Taylor Walker (ORCID: https://orcid.org/0000-0002-2398-4239)
- Tijana Stanic (ORCID: https://orcid.org/0000-0001-6876-8735)
- Edward Thomas Ryan (ORCID: https://orcid.org/0009-0005-0169-394X)
- Regina C. LaRocque (ORCID: https://orcid.org/0000-0003-4558-0339)
- Nora M Mulroy
- Emily P. Hyle (ORCID: https://orcid.org/0000-0001-8721-106X)
- Naomi F. Fields (ORCID: https://orcid.org/0000-0002-1339-4008)
- Satoshi Koiso (ORCID: https://orcid.org/0000-0001-7542-1801)
Institutions
- Centers for Disease Control and Prevention (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Journal of Travel Medicine
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/jtm/taaf053
- Citations
- 2
- Primary Topic
- Travel-related health issues
- Type
- article
- Field-Weighted Citation Impact
- 3.76
Funders
- Centers for Disease Control and Prevention